Janssen Biotech
3 products tracked · names used in filings: Janssen Biotech
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Tue 17 Mar 2026🇺🇸 FDA approval
FDA approves Icotyde (icotrokinra hydrochloride), a new medicine
Janssen Biotech; NDA220149; New molecular entity, Priority review; tablet · source
Fri 13 Feb 2026🇺🇸 FDA approval
FDA approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a new medicine
Janssen Biotech; BLA761484; New biologic; vial · source
Wed 17 Dec 2025🇺🇸 FDA approval
FDA approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a new medicine
Janssen Biotech; BLA761433; New biologic, Priority review; injection · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Icotyde icotrokinra hydrochloride | Approved | 2026-03-17 |
| 🇺🇸 | Rybrevant Faspro amivantamab and hyaluronidase-lpuj | Approved | 2026-02-13 |
| 🇺🇸 | Rybrevant Faspro amivantamab and hyaluronidase-lpuj | Approved | 2025-12-17 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.